Copeptin and Nonalcoholic Fatty Liver Disease
Primary Objective
Determine if copeptin levels, a marker of vasopressin, correlates with presence and severity of fatty liver disease.
Description
See above
Details
Age
Adult
Eligibility
Obese 30-40 BMI, age 30-75Diabetes, other liver disease or eGFR<45.
Locations
Anschutz Health and Wellness
Outpatient CTRC
UCD Anschutz Health & Wellness Center
University of Colorado Hospital
Principal Investigator
Thomas Jensen
Study ID
Protocol Number: 17-1160
More information available at ClinicalTrials.gov: NCT03254563
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers